Dr Norman Hardman joins ValiRx
This article was originally published in Scrip
ValiRx, a UK cancer therapeutics and diagnostics company, has appointed Dr Norman Hardmannon-executive director. He will join the board from September 1st. Dr Hardman is president and CEO of Oxalis Partners, a visiting professor in the college of life sciences and medicine at the University of Aberdeen, and a strategic consultant to US and EU biotechnology companies and VC venture funds.